Evidence map›Paper›PMID 41053454›Full record

ReviewAAPS PharmSciTech2025

The Road to Precision Nanomedicine: An Insight on Drug Repurposing and Advances in Nanoformulations for Treatment of Cancer.

Yasmina Elmahboub, Rofida Albash, Sadek Ahmed, Salwa Salah

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization andJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yasmina ElmahboubDepartment of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, 12585, Egypt. Yasmina.elmahboub@must.edu.eg.ORCID http://orcid.org/0000-0003-1675-335X
Rofida AlbashDepartment of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, 12585, Egypt.
Sadek AhmedDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
Salwa SalahDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the most significant global health challenges, with its burden continuing to rise. The limitations of conventional anticancer therapies caused by the lack of tissue selectivity, demands urgent development of safer and more selective therapies to target tumors. Identifying the fundamental cancer hallmarks provided a comprehensive understanding of cancer biology for effective tumor targeting, encompassing tumor-promoting inflammation, metabolic reprogramming, immune evasion, genomic instability, phenotypic plasticity, epigenetic reprogramming, and polymorphic microbiomes. Moreover, drug repurposing is a cost-effective and time-saving method for cancer therapy that accelerates the drug discovery process by reusing drugs for new indications. Current research is focusing on combining drug repurposing with nanocarriers that enhance tumor targeting, reduce the side effects, and improve the bioavailability of the drug in a single nanoformulation. This article analyzes various types of nanoparticles encapsulating different classes of drugs, such as phenelzine, fexofenadine, telmisartan, losartan, metformin, canagliflozin, atorvastatin, and fenbendazole, highlighting their anticancer effects and the influence of nanocarriers on the drug's therapeutic effect. Results revealed that drug-encapsulated nanoparticles enhanced antitumor effects compared to the free drug solutions. This is attributed to the synergism from the nanocarrier's functionalization, sustained drug release, and improved cellular uptake within tumors that leads to targeting multiple cancer hallmarks. Additionally, this review highlights the present challenges in the clinical translation of nanoformulation and demonstrates how artificial intelligence may facilitate drug screening and identification, therapeutic optimization, and large-scale manufacture. Finally, using these technologies in combination with drug repurposing presents a promising direction for advancing cancer treatment.

Indexed as

Antineoplastic AgentsDrug RepositioningNanomedicineNanoparticlesNeoplasmsPrecision MedicineAnimalsDrug CarriersDrug Delivery SystemsHumansAntineoplastic AgentsDrug Carriersdrug repurposinghallmarks of cancermachine learningsmart nanoparticles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.